US Patent

US12053502 — Daptomycin formulations

Method of Use · Assigned to Xellia Pharmaceuticals ApS · Expires 2038-08-28 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions of daptomycin and at least one amino acid, and their methods of use.

USPTO Abstract

The present invention relates to compositions comprising daptomycin and at least one amino acid, methods of providing such compositions and the uses thereof.

Drugs covered by this patent

Cubicin (Daptomycin) · Baxter

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3981`	—	Cubicin
`U-3981`	—	Cubicin

Patent Metadata

Patent number: US12053502
Jurisdiction: US
Classification: Method of Use
Expires: 2038-08-28
Drug substance claim: No
Drug product claim: No
Assignee: Xellia Pharmaceuticals ApS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.